iwCAR-T 2021

The International Workshop on CAR-T (iwCAR-T) 2021

21–23 April 2021 | Virtual Meeting

VJHemOnc is pleased to be the official media partner for the International Workshop on CAR-T (iwCAR-T) 2021, a high-level discussion forum for research leaders in the field of CAR-T. The world’s leading clinical researchers in the field have shared their perspectives on how to place this evolving understanding in a clinical context and thereby optimize clinical care.

CAR-T in AML CAR-T in ALL CAR-T in CLL CAR-T in Myeloma Evolution of Cellular Therapies Cellular Therapies in Solid Tumors CAR-T in Lymphoma

Session 1: CAR-T in AML

Clinical update on CAR T-cell therapy for AML

Saar Gill Perelman School of Medicine, Philadelphia, PA, United States

Role of CAR T-cells in the treatment of pediatric AML

Richard Aplenc Children's Hospital of Philadelphia, Philadelphia, PA, United States

Marion Subklewe

CAR-T or BITE in AML?

Marion Subklewe LMU Hospital Munich, Munich, Germany

NK-cells and CAR NK-cells for AML

Rizwan Romee Dana-Farber Cancer Institute, Boston, MA, United States

Session 1: Panel discussion

Session 2: CAR-T in ALL

Reuben Benjamin

Allogeneic CAR-Ts for ALL

Reuben Benjamin King’s College Hospital, London, United Kingdom

Factors associated with durable remissions after CAR-T

Cameron Turtle Fred Hutchinson Cancer Research Center, Seattle, WA, Seattle, WA, United States

Adult ALL and CART19

Claire Roddie University College London, London, United Kingdom

Approaches to dual targeting with CAR-Ts

Nirali Shah National Cancer Institute Center for Cancer Research, Bethesda, MD, United States

Bianca Santomasso

Updates on neurotoxicity

Bianca Santomasso Memorial Sloan Kettering Cancer Centre, New York City, NY, United States

Session 2: Panel discussion

Session 3: CAR-T in CLL

Jordan Gauthier

Combining ibrutinib with CD19 CAR T-cells for CLL

Jordan Gauthier Fred Hutchinson Cancer Research Center, Seattle, WA, United States

Transcend/JCAR – lisocabtagene maraleucel (liso-cel)

Tanya Siddiqi City of Hope, Duarte, CA, United States

CAR T-cells for CLL: When can we use the word ‘cure’?

David Porter University of Pennsylvania, Philadelphia, PA, United States

Session 3: Panel discussion

Session 4: CAR-T in Myeloma

BCMA CAR-Ts – idecabtagene vicleucel (ide-cel)/bb2121

Nina Shah University of California, San Francisco, CA, United States

Ciltacabtagene autoleucel (cilta-cel) – CARTITUDE

Saad Usmani Memorial Sloan Kettering Cancer Center, New York, NY, United States

Sham Mailankody

Allo-CAR-T

Sham Mailankody Memorial Sloan Kettering Cancer Centre, New York City, NY, United States

TCE – BCMA and non-BCMA targets

Adam Cohen University of Pennsylvania, Philadelphia, PA, United States

Maria-Victoria Mateos

BiTEs vs CARs

Maria-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain

Session 4: Panel discussion

Session 5: Evolution of Cellular Therapies

Logic-gated cell therapy

William Go A2 Biotherapeutics, Agoura Hills, CA, United States

Renier Bretjens

Innovative CAR designs

Renier Bretjens Memorial Sloan Kettering Cancer Centre, New York City, NY, United States

Session 5: Panel discussion

Session 6: Where Are We with Emerging Cell Therapies in Solid Tumors?

Sébastien Anguille

alloSHRINK – non-gene edited allogeneic CAR-T in mCRC

Sébastien Anguille University of Antwerp, Antwerp, Belgium

CAR T-cells in mCRPC

Vivek Narayan University of Pennsylvania, Philadelphia, PA, United States

Jennifer Specht

ROR-1 in breast and lung cancer

Jennifer Specht Seattle Cancer Care Alliance, Seattle, WA, United States

Christine Brown

CAR T-cell therapy in glioblastoma

Christine Brown The Beckman Research Institute of City of Hope, Duarte, CA, United States

Session 6: Panel discussion (part one)

Stanley Riddell

Signaling in solid tumors

Stanley Riddell Fred Hutchinson Cancer Research Center, Seattle, WA, United States

Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4

David Hong The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States

Auto TILs lifileucel (LN-144) for metastatic melanoma

Amod Sarnaik H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Melissa Johnson

Cell therapy trial updates in lung cancer and mesothelioma

Melissa Johnson Sarah Cannon Cancer Institute, Nashville, TN, United States

Session 6: Panel discussion (part two)

Session 7: CAR-T in Lymphoma

Axicabtagene ciloleucel (axi-cel) in DLBCL and FL

Caron Jacobson Dana-Farber Cancer Institute, Boston, MA, United States

Stephen Schuster

Tisagenlecleucel in DLBCL/FL

Stephen Schuster Perelman School of Medicine, Philadelphia, PA, United States

Jeremy Abramson

Lisocabtagene maraleucel (liso-cel) in DLBCL

Jeremy Abramson Massachusetts General Hospital Cancer Center, Boston, MA, United States

Frederick Locke

Updates in MCL

Frederick Locke H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Dual CARs

David Miklos Stanford University, Stanford, CA, United States

Third generation CD20-targeted CAR T-cell therapy

Mazyar Shadman Fred Hutchinson Cancer Research Center, Seattle, WA, United States

A new era of targeted therapy

Sonali Smith University of Chicago, Chicago, IL, United States

Session 7: Panel discussion

Visit the CAR-T and Cellular Therapy Focus for the latest updates from leading experts